NO20002655L - 5-(2-imidazolinylamino) -benzimidazol derivater, fremstilling og anvendelse derav som <alfa>-adrenoceptoragonister med forbedret metabolisk stabilitet - Google Patents

5-(2-imidazolinylamino) -benzimidazol derivater, fremstilling og anvendelse derav som <alfa>-adrenoceptoragonister med forbedret metabolisk stabilitet

Info

Publication number
NO20002655L
NO20002655L NO20002655A NO20002655A NO20002655L NO 20002655 L NO20002655 L NO 20002655L NO 20002655 A NO20002655 A NO 20002655A NO 20002655 A NO20002655 A NO 20002655A NO 20002655 L NO20002655 L NO 20002655L
Authority
NO
Norway
Prior art keywords
imidazolinylamino
alfa
preparation
metabolic stability
benzimidazole derivatives
Prior art date
Application number
NO20002655A
Other languages
English (en)
Norwegian (no)
Other versions
NO20002655D0 (no
Inventor
Thomas Lee Cupps
Sophie Lee Bogdan
Nicholas Nikolaides
Sheri Ann Gilbert
Michael Gazda
Roy Lee Martin Dobson
Charles Andrew Cruze Iii
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of NO20002655D0 publication Critical patent/NO20002655D0/no
Publication of NO20002655L publication Critical patent/NO20002655L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20002655A 1997-11-24 2000-05-24 5-(2-imidazolinylamino) -benzimidazol derivater, fremstilling og anvendelse derav som <alfa>-adrenoceptoragonister med forbedret metabolisk stabilitet NO20002655L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6676797P 1997-11-24 1997-11-24
US6670097P 1997-11-25 1997-11-25
PCT/US1998/024694 WO1999026942A1 (en) 1997-11-24 1998-11-20 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability

Publications (2)

Publication Number Publication Date
NO20002655D0 NO20002655D0 (no) 2000-05-24
NO20002655L true NO20002655L (no) 2000-07-24

Family

ID=26747058

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002655A NO20002655L (no) 1997-11-24 2000-05-24 5-(2-imidazolinylamino) -benzimidazol derivater, fremstilling og anvendelse derav som <alfa>-adrenoceptoragonister med forbedret metabolisk stabilitet

Country Status (23)

Country Link
US (1) US6486190B1 (sk)
EP (1) EP1037887B1 (sk)
JP (1) JP2001524478A (sk)
KR (1) KR20010032435A (sk)
CN (1) CN1284073A (sk)
AT (1) ATE271048T1 (sk)
BR (1) BR9815017A (sk)
CA (1) CA2311344C (sk)
CO (1) CO4970802A1 (sk)
DE (1) DE69825075T2 (sk)
ES (1) ES2223143T3 (sk)
HU (1) HUP0101469A3 (sk)
IL (1) IL136303A (sk)
IN (1) IN190809B (sk)
NO (1) NO20002655L (sk)
NZ (1) NZ504707A (sk)
PE (1) PE133699A1 (sk)
PL (1) PL340711A1 (sk)
RU (1) RU2193562C2 (sk)
SK (1) SK7792000A3 (sk)
TR (1) TR200002242T2 (sk)
TW (1) TW505642B (sk)
WO (1) WO1999026942A1 (sk)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1385823B1 (en) 2001-04-09 2006-12-13 Chiron Corporation Guanidino compounds as melanocortin-4 receptor (mc4-r) agonists
FR2842422B1 (fr) * 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
US20040167194A1 (en) 2003-02-20 2004-08-26 Randall Jared Lynn Methods of making 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form
KR101053816B1 (ko) * 2003-02-20 2011-08-03 론자 아게 Ｎ-치환된 포름아미드의 제조 방법
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
MXPA06013649A (es) * 2004-05-25 2007-07-09 Sansrosa Pharmaceutical Dev In Compuestos, formulaciones, y metodos para tratar o prevenir desordenes inflamatorios de la piel.
EP2218442A1 (en) 2005-11-09 2010-08-18 CombinatoRx, Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
EP2819674A2 (en) * 2012-02-27 2015-01-07 Eye Therapies LLC Compositions and methods for the treatment of migraine
US20150133516A1 (en) * 2013-11-13 2015-05-14 Brian K. Adams Methods and Compositions for Treating ADHD
CA3006563A1 (en) * 2015-11-30 2017-06-08 Catherine Crisp TURKEL Compositions and methods for otologic prophylaxis and treatment
EA030197B1 (ru) * 2016-03-22 2018-07-31 Общество С Ограниченной Ответственностью "Рубикон" Таблетированная форма противовирусного лекарственного средства
JP7163014B2 (ja) * 2016-10-31 2022-10-31 エスエス製薬株式会社 感冒薬

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4029792A (en) 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US4036976A (en) 1973-04-05 1977-07-19 Sandoz, Inc. Substituted imidazolinylamino-indazoles
US4217356A (en) 1975-08-22 1980-08-12 Sandoz Ltd. 2-Imidazolinylamino-2,1,3-benzothiadiazoles
US4398028A (en) 1977-01-14 1983-08-09 Sandoz Ltd. Bicyclic heterocyclic amino derivatives
EP0025269B1 (en) 1979-08-23 1985-11-13 Beecham Group Plc Anti-diarrhoea veterinary composition
JPS57501378A (sk) 1980-09-05 1982-08-05
FR2638356A1 (fr) 1988-10-28 1990-05-04 Anben Nouveaux derives de la 2-arylimino-imidazolidine pour diminuer la pression intra-oculaire et traiter le glaucome
US5281591A (en) 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5180721A (en) 1989-05-22 1993-01-19 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5231096A (en) 1989-10-12 1993-07-27 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5091528A (en) 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
US5478858A (en) 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
WO1996004270A1 (en) * 1994-08-04 1996-02-15 Synaptic Pharmaceutical Corporation Novel benzimidazole derivatives
ID24081A (id) * 1997-04-15 2000-07-06 Procter & Gamble Senyawa-senyawa 5-(2-imidazolinilamino) benzimidazol yang berguna sebagai agonis-agonis alfa-2-adrenoseptor

Also Published As

Publication number Publication date
US6486190B1 (en) 2002-11-26
JP2001524478A (ja) 2001-12-04
PL340711A1 (en) 2001-02-26
CN1284073A (zh) 2001-02-14
DE69825075T2 (de) 2005-08-25
KR20010032435A (ko) 2001-04-25
DE69825075D1 (de) 2004-08-19
CA2311344A1 (en) 1999-06-03
IL136303A (en) 2004-02-08
WO1999026942A8 (en) 2000-08-03
SK7792000A3 (en) 2001-01-18
TW505642B (en) 2002-10-11
NO20002655D0 (no) 2000-05-24
EP1037887A1 (en) 2000-09-27
PE133699A1 (es) 2000-03-05
HUP0101469A3 (en) 2003-01-28
IN190809B (sk) 2003-08-23
TR200002242T2 (tr) 2000-11-21
CO4970802A1 (es) 2000-11-07
HUP0101469A2 (hu) 2001-10-28
EP1037887B1 (en) 2004-07-14
NZ504707A (en) 2002-11-26
ES2223143T3 (es) 2005-02-16
RU2193562C2 (ru) 2002-11-27
BR9815017A (pt) 2001-09-11
WO1999026942A1 (en) 1999-06-03
IL136303A0 (en) 2001-05-20
CA2311344C (en) 2006-02-07
ATE271048T1 (de) 2004-07-15

Similar Documents

Publication Publication Date Title
NO20002655L (no) 5-(2-imidazolinylamino) -benzimidazol derivater, fremstilling og anvendelse derav som &lt;alfa&gt;-adrenoceptoragonister med forbedret metabolisk stabilitet
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
TR200201004T2 (tr) Monoamin reuptake önleyicileri olarak biaril eter türevleri
MY134568A (en) Cb2 receptor agonists
DE602004012858D1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
DE69823843D1 (de) Benzimidazolinone, benzoxazolinone, benzopiperazinone, indanone und deren derivate als faktor xa inhibitoren
HRP941000B9 (hr) Morfolin i tiomorfolin antagonisti receptora tahikinina
EE9900217A (et) Sulfiinhappe derivaadid, nende valmistamine ja kasutamine
TR200200649T2 (tr) Farmasötik özelliklere sahip olan yeni aminodikarboksilik asit türevleri
DE60215000D1 (de) DIHYDROPYRROLOi1,2-AöINDOL- UND TETRAHYDROPYRIDOi1,2-AöINDOLDERIVATE ALS PROSTAGLANDIN REZEPTOR ANTAGONISTEN
DK1697370T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
DE122008000037I1 (de) Morpholinwirkstoffvorläufer als tachykininreceptorantagonisten
DE602006007556D1 (de) Heteroarylsulfonylstilbene als 5-ht2a-antagonisten
FI954944A (fi) Indolijohdannaisia 5-HT1-kaltaisina agonisteina käytettäväksi migreenin hoitoon
DE60230127D1 (de) Inhibitoren von integrin alpha-v-beta-6
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
BR0315644A (pt) Piperazinil e diazapanil benzamidas e benzotioamidas
BR0007864A (pt) Composto, e, uso de um composto
DE50309320D1 (de) C10-alkanolalkoxylate und ihre verwendung
SE0102055D0 (sv) New Compounds
DK1246808T3 (da) 1,2-diarylbenzimidazoler til behandling af sygdomme, som er associeret med en mikroglia-aktivering
DE60112960D1 (de) Kondensierte pyridoindolderivate
TR199500956A2 (tr) Benzimidazol türevleri.
RS20060072A (en) Aminoquinoline derivatives and their use as adenosine a3 ligands
PT1204658E (pt) Agonistas benzofurilpiperazina de serotonina

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application